IN2009DN05670A - - Google Patents
Download PDFInfo
- Publication number
- IN2009DN05670A IN2009DN05670A IN5670DEN2009A IN2009DN05670A IN 2009DN05670 A IN2009DN05670 A IN 2009DN05670A IN 5670DEN2009 A IN5670DEN2009 A IN 5670DEN2009A IN 2009DN05670 A IN2009DN05670 A IN 2009DN05670A
- Authority
- IN
- India
- Prior art keywords
- carbolines
- producing
- intermediates
- fused gamma
- methods
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90647307P | 2007-03-12 | 2007-03-12 | |
PCT/US2008/003340 WO2008112280A1 (en) | 2007-03-12 | 2008-03-12 | Substituted heterocycle fused gamma-carbolines synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2009DN05670A true IN2009DN05670A (enrdf_load_html_response) | 2015-07-24 |
Family
ID=39759858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5670DEN2009 IN2009DN05670A (enrdf_load_html_response) | 2007-03-12 | 2008-03-12 |
Country Status (12)
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5567349B2 (ja) | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
JP5501251B2 (ja) | 2008-01-11 | 2014-05-21 | アルバニー モレキュラー リサーチ, インコーポレイテッド | Mch拮抗薬としての(1−アジノン)置換ピリドインドール類 |
HRP20141178T1 (hr) | 2008-03-12 | 2015-04-10 | Intra-Cellular Therapies, Inc. | Äśvrsti gama karbolin kondenziran sa supstituiranim heterociklusom |
WO2009145900A1 (en) | 2008-05-27 | 2009-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
US9107696B2 (en) * | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
EP2344505A2 (en) | 2008-09-29 | 2011-07-20 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
WO2011003005A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
WO2011133224A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
JP6242855B2 (ja) | 2012-04-14 | 2017-12-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
ES2846823T3 (es) | 2013-03-15 | 2021-07-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
RU2682658C1 (ru) * | 2013-12-03 | 2019-03-20 | Интра-Селлулар Терапиз, Инк. | Новые способы |
MX365969B (es) | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
AU2015240526A1 (en) | 2014-04-04 | 2016-11-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
US10253024B2 (en) | 2015-04-30 | 2019-04-09 | The Regents Of The University Of Colorado, A Body Corporate | Polycyclic indoline and indolenine compounds |
CN113786407B (zh) | 2016-01-26 | 2024-05-24 | 细胞内治疗公司 | 有机化合物 |
IL281050B2 (en) | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
JP2019513143A (ja) * | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規塩類および結晶 |
WO2017172811A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
US11332469B2 (en) | 2016-08-09 | 2022-05-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of lumateperone ditosylate salt |
EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | Compounds for increasing neural plasticity |
EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
JP7132939B2 (ja) | 2017-03-24 | 2022-09-07 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規組成物および方法 |
JP2020513023A (ja) | 2017-04-10 | 2020-04-30 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ルマテペロンp−トシラートの非晶質形態および固体分散体 |
EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規な塩および結晶 |
EP3717484A4 (en) | 2017-11-27 | 2021-08-04 | Egis Gyógyszergyár Zrt. | PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT |
US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
IL277509B2 (en) | 2018-03-23 | 2023-11-01 | Intra Cellular Therapies Inc | Organic compounds |
CN112384218B (zh) | 2018-06-06 | 2024-04-26 | 细胞内治疗公司 | 盐和晶体 |
EP3801527B1 (en) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Fused gamma-carbolines for acute treatment of anxiety or depression |
CA3240552A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
CN112585690B (zh) | 2018-06-21 | 2025-04-15 | 阿奎斯蒂弗医疗股份有限公司 | 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法 |
HUE067912T2 (hu) | 2018-08-13 | 2024-11-28 | Hoffmann La Roche | Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok |
JP2022500362A (ja) | 2018-08-29 | 2022-01-04 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
CN112955124A (zh) | 2018-09-07 | 2021-06-11 | 阿奎蒂夫疗法公司 | 具有精确的活性物溶出谱的口腔膜组合物和剂型 |
US20220024924A1 (en) | 2018-11-27 | 2022-01-27 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
MX2021007141A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
MX2021007143A (es) | 2018-12-17 | 2021-08-18 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
CA3121635A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Serotonin 5-ht2a receptor antagonist |
JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
EP3897621A4 (en) | 2018-12-21 | 2022-09-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR20210134689A (ko) | 2019-02-27 | 2021-11-10 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
KR20220126286A (ko) | 2019-11-01 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 전구약물 조성물 및 치료 방법 |
CN110698474B (zh) * | 2019-11-14 | 2021-11-02 | 福州大学 | 一种α位取代四氢-γ-咔啉类化合物及其制备方法和应用 |
BR112022008784A2 (pt) | 2019-11-14 | 2022-07-26 | Aquestive Therapeutics Inc | Composições multimodais e métodos de tratamento |
US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
US20210186962A1 (en) | 2019-12-19 | 2021-06-24 | Intra-Cellular Therapies, Inc. | Methods of schizophrenia treatment |
CN112062767B (zh) * | 2020-10-20 | 2022-03-11 | 杭州科巢生物科技有限公司 | 一种卢美哌隆的制备方法及其中间体 |
US20220233471A1 (en) | 2021-01-15 | 2022-07-28 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
US20220347117A1 (en) | 2021-03-09 | 2022-11-03 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
CN113024554B (zh) * | 2021-03-24 | 2023-03-14 | 上海法默生物科技有限公司 | 一种卢美哌隆中间体的制备方法 |
CN114105980B (zh) * | 2021-12-13 | 2024-04-16 | 南方科技大学坪山生物医药研究院 | 卢美哌隆中间体化合物的制备方法及卢美哌隆中间体化合物 |
CN114105985B (zh) * | 2021-12-13 | 2024-04-16 | 南方科技大学坪山生物医药研究院 | 不对称氢化构建卢美哌隆中间体的方法及卢美哌隆中间体 |
EP4448531A1 (en) | 2021-12-15 | 2024-10-23 | Delix Therapeutics, Inc. | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof |
US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
KR20250123225A (ko) | 2022-12-30 | 2025-08-14 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
WO2024173901A1 (en) | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
CN119912455B (zh) * | 2025-01-22 | 2025-09-23 | 成都臻拓医药科技有限公司 | 一种卢美哌隆中间体化合物的制备方法 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US38679A (en) | 1863-05-26 | Improvement in water-elevators | ||
US39680A (en) | 1863-08-25 | Improvement in machines for breaking and cleaning flax | ||
US6713A (en) | 1849-09-11 | Hobse-poweb | ||
US471A (en) | 1837-11-20 | Mode of | ||
US2490813A (en) * | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
US3299078A (en) * | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
US3813392A (en) * | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
US4238607A (en) * | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
US4183936A (en) * | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US3914421A (en) * | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
US4115577A (en) * | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US4219550A (en) * | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
US4522944A (en) * | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
ZA871987B (en) * | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
JP2641443B2 (ja) * | 1986-04-07 | 1997-08-13 | クミアイ化学工業株式会社 | 5H−1,3,4−チアジアゾロ〔3,2−a〕ピリミジン−5−オン誘導体及びこれを有効成分とする農園芸用殺菌剤 |
US5576460A (en) * | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
US5654482A (en) * | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
US5648542A (en) * | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
US5648539A (en) * | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
US5847166A (en) * | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
US5705697A (en) * | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
US5723671A (en) * | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US6323366B1 (en) * | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
GB2328686B (en) * | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
US6395939B1 (en) * | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
US6235936B1 (en) * | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
EP1058678B1 (en) | 1998-02-26 | 2002-12-11 | Massachusetts Institute of Technology | Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes |
US5902901A (en) * | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
US7223879B2 (en) * | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US6395916B1 (en) * | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
ATE316532T1 (de) | 1998-07-10 | 2006-02-15 | Massachusetts Inst Technology | Liganden für metalle und metall-katalysiertes verfahren |
US6307087B1 (en) * | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US20010008942A1 (en) * | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
US6407092B1 (en) * | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
IL147108A0 (en) * | 1999-06-15 | 2002-08-14 | Du Pont Pharm Co | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) * | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US6541639B2 (en) * | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
RU2003121304A (ru) * | 2000-12-20 | 2005-01-27 | Бристол-Маерс Сквибб Компани (Us) | Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
WO2002085838A1 (en) * | 2001-04-24 | 2002-10-31 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
MXPA04001203A (es) * | 2001-08-08 | 2004-05-20 | Pharmacia & Upjhon Company | 1-h-pirido[4,3-b] indoles terapeuticos. |
AU2003257062A1 (en) * | 2002-08-02 | 2004-02-23 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
JP4486505B2 (ja) * | 2002-12-19 | 2010-06-23 | ブリストル−マイヤーズ スクイブ カンパニー | セロトニン・レセプタ作用薬および拮抗薬としての置換トリ環式ガンマ−カルボリン化合物 |
JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
US7592454B2 (en) * | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
KR100883003B1 (ko) * | 2004-12-15 | 2009-02-12 | 에프. 호프만-라 로슈 아게 | 알츠하이머병의 치료를 위한 글라이신 수송체1(glyt-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온 |
JP5567349B2 (ja) | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
HRP20141178T1 (hr) | 2008-03-12 | 2015-04-10 | Intra-Cellular Therapies, Inc. | Äśvrsti gama karbolin kondenziran sa supstituiranim heterociklusom |
WO2009145900A1 (en) | 2008-05-27 | 2009-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
WO2011133224A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP6242855B2 (ja) | 2012-04-14 | 2017-12-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
ES2846823T3 (es) | 2013-03-15 | 2021-07-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
RU2682658C1 (ru) | 2013-12-03 | 2019-03-20 | Интра-Селлулар Терапиз, Инк. | Новые способы |
MX365969B (es) | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
IL281050B2 (en) | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
EP3717484A4 (en) | 2017-11-27 | 2021-08-04 | Egis Gyógyszergyár Zrt. | PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT |
-
2008
- 2008-03-12 JP JP2009553626A patent/JP5567349B2/ja active Active
- 2008-03-12 MX MX2020001497A patent/MX394214B/es unknown
- 2008-03-12 KR KR1020197019369A patent/KR102065319B1/ko active Active
- 2008-03-12 KR KR1020157033684A patent/KR101981840B1/ko active Active
- 2008-03-12 DK DK08742074.1T patent/DK2134710T3/da active
- 2008-03-12 EP EP20153727.1A patent/EP3663294A1/en active Pending
- 2008-03-12 ES ES08742074T patent/ES2776889T3/es active Active
- 2008-03-12 CN CN2008800157710A patent/CN101796051B/zh active Active
- 2008-03-12 WO PCT/US2008/003340 patent/WO2008112280A1/en active Application Filing
- 2008-03-12 AU AU2008226814A patent/AU2008226814C1/en active Active
- 2008-03-12 US US12/531,016 patent/US8309722B2/en active Active
- 2008-03-12 IN IN5670DEN2009 patent/IN2009DN05670A/en unknown
- 2008-03-12 CA CA2679754A patent/CA2679754C/en active Active
- 2008-03-12 KR KR1020207012082A patent/KR102238390B1/ko active Active
- 2008-03-12 KR KR1020097019338A patent/KR101805914B1/ko active Active
- 2008-03-12 EP EP08742074.1A patent/EP2134710B1/en active Active
- 2008-03-12 KR KR1020197013610A patent/KR102107954B1/ko active Active
- 2008-03-12 KR KR1020187017827A patent/KR101999300B1/ko active Active
- 2008-03-12 MX MX2009009773A patent/MX2009009773A/es active IP Right Grant
- 2008-03-12 KR KR1020217009724A patent/KR102372149B1/ko active Active
- 2008-03-12 CN CN201310464631.4A patent/CN103626766B/zh active Active
-
2009
- 2009-09-11 MX MX2022008904A patent/MX2022008904A/es unknown
-
2012
- 2012-08-23 US US13/593,097 patent/US8779139B2/en active Active
-
2014
- 2014-06-19 JP JP2014126495A patent/JP5918306B2/ja active Active
- 2014-06-26 AU AU2014203483A patent/AU2014203483B2/en active Active
- 2014-07-03 US US14/323,545 patent/US9315504B2/en active Active
-
2016
- 2016-03-10 US US15/066,962 patent/US9751883B2/en active Active
- 2016-04-07 JP JP2016077538A patent/JP6231151B2/ja active Active
- 2016-09-27 AU AU2016234905A patent/AU2016234905B2/en active Active
-
2017
- 2017-07-26 US US15/660,762 patent/US10221176B2/en active Active
- 2017-10-18 JP JP2017201937A patent/JP6522710B2/ja active Active
-
2018
- 2018-03-14 AU AU2018201818A patent/AU2018201818B2/en active Active
-
2019
- 2019-01-10 US US16/244,796 patent/US10597395B2/en active Active
- 2019-04-24 JP JP2019082541A patent/JP6773837B2/ja active Active
- 2019-06-12 US US16/439,361 patent/US10464938B2/en active Active
- 2019-09-10 AU AU2019229334A patent/AU2019229334B2/en active Active
- 2019-10-07 US US16/594,603 patent/US11407751B2/en active Active
- 2019-12-12 US US16/711,790 patent/US11066407B2/en active Active
-
2020
- 2020-10-01 JP JP2020166874A patent/JP2021006559A/ja not_active Withdrawn
-
2022
- 2022-06-24 US US17/808,836 patent/US12139490B2/en active Active
- 2022-09-09 JP JP2022144080A patent/JP2022180440A/ja active Pending
-
2024
- 2024-10-03 US US18/905,607 patent/US20250101022A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2009DN05670A (enrdf_load_html_response) | ||
TW200604184A (en) | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | |
PH12013502230A1 (en) | Multispecific antibodies | |
MY181898A (en) | Heterocyclic compounds and uses thereof | |
UA104459C2 (uk) | Антитіла проти fgfr3 і способи їх застосування | |
TN2011000673A1 (en) | Bace inhibitors | |
MX2010004374A (es) | Armazones proteinicos. | |
MX2011001679A (es) | Derivados de flavina. | |
PH12012501346A1 (en) | Heteroaryl compounds and uses thereof | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
MY152749A (en) | Pyrazole and fused pyrazole glucokinase activators | |
SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MY170720A (en) | Antibody formulations | |
CA2705357C (en) | Formulations for taci-immunoglobulin fusion proteins | |
MX2012002387A (es) | Aminas de triazol fusionadas como moduladores p2x7. | |
PH12013500500A1 (en) | Fused heteroaryls and their uses | |
MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
TW200624426A (en) | BACE inhibitors | |
MX2009004030A (es) | Articulos antimicrobianos y metodos de fabricacion. | |
WO2009015037A3 (en) | 5-pyridinone substituted indazoles | |
PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
WO2008085900A3 (en) | Methods for generating novel stabilized proteins | |
IL200000A0 (en) | Process for the preparation of 2-substituted-5-(1-alkylthio) alkylpyridines |